Alliance-A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients With Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy With HER2 Blockade

Objective

This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab.

National Clinical Trial (NCT) Number: 06876714

National Library of Medicine clinicaltrials.gov Website Address: https://clinicaltrials.gov/study/NCT06876714

Location: Essentia Health Cancer Centers

Research Study Categories

• Adult Oncology Studies

Specialties

• Breast Cancer

Contact

Cancer Clinical Trials at 218-786-3308 or 844-681-7944, [email protected]